Cargando…

Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer

PURPOSE: To investigate prognostic values of prostatic urethra involvement (PUI) and construct a prognostic model that estimates the probability of cancer-specific survival for T1 bladder cancer patients. METHOD AND MATERIALS: We investigated the national Surveillance, Epidemiology, and End Results...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Hao, Zhan, Xiangpeng, Li, Xuwen, Chen, Tao, Deng, Xinxi, Liu, Yang, Deng, Jun, Fu, Bin, Li, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638768/
https://www.ncbi.nlm.nih.gov/pubmed/37950252
http://dx.doi.org/10.1186/s12894-023-01342-2
_version_ 1785133667003138048
author Wan, Hao
Zhan, Xiangpeng
Li, Xuwen
Chen, Tao
Deng, Xinxi
Liu, Yang
Deng, Jun
Fu, Bin
Li, Yu
author_facet Wan, Hao
Zhan, Xiangpeng
Li, Xuwen
Chen, Tao
Deng, Xinxi
Liu, Yang
Deng, Jun
Fu, Bin
Li, Yu
author_sort Wan, Hao
collection PubMed
description PURPOSE: To investigate prognostic values of prostatic urethra involvement (PUI) and construct a prognostic model that estimates the probability of cancer-specific survival for T1 bladder cancer patients. METHOD AND MATERIALS: We investigated the national Surveillance, Epidemiology, and End Results (SEER) database (2004–2015) to get patients diagnosed with T1 bladder cancer. An external validation cohort was obtained from the First Affiliated Hospital of Nanchang University. The Kaplan–Meier method with the log-rank test was applied to assess cancer-specific survival (CSS) and overall survival (OS). Moreover, the propensity score matching (PSM) and multivariable Cox proportional hazard model were performed. All patients were randomly divided into the development cohort and validation group at the ratio of 7:3. The performance of the model was internally validated by calibration curves and the concordance index (C-index). RESULTS: The PUI group had a lower survival rate of both CSS and overall survival OS before and after PSM when compared to non-involved patients (All P < 0.05). Multivariate analysis revealed a poor prognosis in the PUI group for cancer-specific mortality (CSM) and all-cause mortality (ACM) analyses before and after PSM (All P < 0.05). Seven variables, including age, surgery, radiotherapy, tumour size, PUI, and marital status, were incorporated in the final nomogram. The C-index in the development cohort was 0.715 (0.711–0.719), while it was 0.672 (0.667–0.677) in the validation group. Calibration plots for 3- and 5-year cancer-specific survival showed good concordance in the development and validation cohorts. CONCLUSIONS: PUI was an independent risk factor of ACM and CSM in T1 bladder cancer patients. In addition, a highly discriminative and precise nomogram that predicted the individualized probability of cancer-specific survival for patients with T1 bladder cancer was constructed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-023-01342-2.
format Online
Article
Text
id pubmed-10638768
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106387682023-11-11 Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer Wan, Hao Zhan, Xiangpeng Li, Xuwen Chen, Tao Deng, Xinxi Liu, Yang Deng, Jun Fu, Bin Li, Yu BMC Urol Research PURPOSE: To investigate prognostic values of prostatic urethra involvement (PUI) and construct a prognostic model that estimates the probability of cancer-specific survival for T1 bladder cancer patients. METHOD AND MATERIALS: We investigated the national Surveillance, Epidemiology, and End Results (SEER) database (2004–2015) to get patients diagnosed with T1 bladder cancer. An external validation cohort was obtained from the First Affiliated Hospital of Nanchang University. The Kaplan–Meier method with the log-rank test was applied to assess cancer-specific survival (CSS) and overall survival (OS). Moreover, the propensity score matching (PSM) and multivariable Cox proportional hazard model were performed. All patients were randomly divided into the development cohort and validation group at the ratio of 7:3. The performance of the model was internally validated by calibration curves and the concordance index (C-index). RESULTS: The PUI group had a lower survival rate of both CSS and overall survival OS before and after PSM when compared to non-involved patients (All P < 0.05). Multivariate analysis revealed a poor prognosis in the PUI group for cancer-specific mortality (CSM) and all-cause mortality (ACM) analyses before and after PSM (All P < 0.05). Seven variables, including age, surgery, radiotherapy, tumour size, PUI, and marital status, were incorporated in the final nomogram. The C-index in the development cohort was 0.715 (0.711–0.719), while it was 0.672 (0.667–0.677) in the validation group. Calibration plots for 3- and 5-year cancer-specific survival showed good concordance in the development and validation cohorts. CONCLUSIONS: PUI was an independent risk factor of ACM and CSM in T1 bladder cancer patients. In addition, a highly discriminative and precise nomogram that predicted the individualized probability of cancer-specific survival for patients with T1 bladder cancer was constructed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-023-01342-2. BioMed Central 2023-11-10 /pmc/articles/PMC10638768/ /pubmed/37950252 http://dx.doi.org/10.1186/s12894-023-01342-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wan, Hao
Zhan, Xiangpeng
Li, Xuwen
Chen, Tao
Deng, Xinxi
Liu, Yang
Deng, Jun
Fu, Bin
Li, Yu
Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer
title Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer
title_full Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer
title_fullStr Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer
title_full_unstemmed Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer
title_short Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer
title_sort assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for t1 stage bladder cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638768/
https://www.ncbi.nlm.nih.gov/pubmed/37950252
http://dx.doi.org/10.1186/s12894-023-01342-2
work_keys_str_mv AT wanhao assessingtheprognosticimpactofprostaticurethrainvolvementanddevelopinganomogramfort1stagebladdercancer
AT zhanxiangpeng assessingtheprognosticimpactofprostaticurethrainvolvementanddevelopinganomogramfort1stagebladdercancer
AT lixuwen assessingtheprognosticimpactofprostaticurethrainvolvementanddevelopinganomogramfort1stagebladdercancer
AT chentao assessingtheprognosticimpactofprostaticurethrainvolvementanddevelopinganomogramfort1stagebladdercancer
AT dengxinxi assessingtheprognosticimpactofprostaticurethrainvolvementanddevelopinganomogramfort1stagebladdercancer
AT liuyang assessingtheprognosticimpactofprostaticurethrainvolvementanddevelopinganomogramfort1stagebladdercancer
AT dengjun assessingtheprognosticimpactofprostaticurethrainvolvementanddevelopinganomogramfort1stagebladdercancer
AT fubin assessingtheprognosticimpactofprostaticurethrainvolvementanddevelopinganomogramfort1stagebladdercancer
AT liyu assessingtheprognosticimpactofprostaticurethrainvolvementanddevelopinganomogramfort1stagebladdercancer